ILLUMINATE 301 Will Study Experimental Immunotherapy for Patients With Advanced Melanoma

Investigators are now enrolling for a phase III trial testing the experimental immunotherapy tilsotolimod plus ipilimumab in patients with advanced melanoma who have progressed on anti –PD-1 therapy.

Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news